ReviewTranslational oncology2024
Role of glucose metabolic reprogramming in colorectal cancer progression and drug resistance.
Review in Translational oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Mitochondrial metabolite transporters at the crossroads of metabolic reprogramming, epigenetic regulation and therapeutic vulnerabilities in colorectal cancer.Molecular biology reports · 2026Review
- A Novel tRNA Half mt-5'-tiRNA-Tyr Promotes Colorectal Cancer Proliferation via Inducing HARS2 Succinylation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- METTL3-YTHDF1-driven mMolecular and cellular biochemistry · 2026Article
- HighTranslational cancer research · 2026Article
- Integrative single-cell and multi-omics analysis of ZBTB21-mediated serine metabolism in colorectal cancer: from metabolic reprogramming to immune microenvironment modulation.Cancer immunology, immunotherapy : CII · 2026Article
- Review
- Exercise serum promotes DNA damage repair and remodels gene expression in colon cancer cells.International journal of cancer · 2026Article
- Integrative single-cell and spatial multi-Omics analyses identify NETs-driven colon cancer subtypes with distinct metabolic features and prognostic implications.Journal of translational medicine · 2026Article
- Diagnostic Potential of Exosomes in Colorectal Cancer: Current Advances and Future Perspectives.Molecules (Basel, Switzerland) · 2026Review
- FBXO39 promotes LDHA-mediated aerobic glycolysis and colorectal cancer progression by p53 degradation.Journal of translational medicine · 2026Article
- Fusobacterium nucleatum promotes tumor progression driven by histone lactylation through increasing GLUT1 expression in colorectal cancer.Journal of translational medicine · 2026Article
- Splice-switching of the oncogenic BCS1L isoform suppresses ovarian cancer progression by disrupting mitochondrial function.Cell death & disease · 2026Article
- A TXNIP-driven bioluminescent reporter for high-throughput discovery of glycolytic inhibitors against renal cell carcinoma.BMC biotechnology · 2026Article
- RPS2 and EEF1B2 are associated with glycolysis-related malignant phenotypes in COAD.American journal of cancer research · 2026Article
- GSG2 promotes aerobic glycolysis and colorectal cancer progression via the MDM2-p53 axis.American journal of cancer research · 2026Article
- High Glycolysis and Lipid Metabolism Status Predicts Poor Prognosis in Colorectal Cancer Patients.Current molecular medicine · 2026Article
- The Role of Gut Microbiota in Colorectal Cancer Pathogenesis: A Comprehensive Literature Review.International journal of molecular sciences · 2025Review
- The metabolic crossroads: glycolysis in cancer and neurodegeneration.BMC neurology · 2025Article
- Article
- Restricting metabolic plasticity enhances stress adaptation through the modulation of PDH and HIF1A in TRAP1-depleted colon cancer.Cancer letters · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC), with the incidence and mortality rising on a yearly basis, greatly threatens people's health. It is considered an important hallmark of tumorigenesis that aberrant glucose metabolism in cancer cells, particularly the Warburg effect. In CRC, the Warburg effect predominantly influences cancer development and progression via its involvement in the glycolytic pathway regarding cell metabolism. The critical mechanisms underlying this process include key glycolytic enzymes, transport proteins, regulatory molecules, and signaling pathways. Furthermore, targeting the reprogrammed glucose metabolism in cancer cells can be potentially used for CRC treatment. However, the mechanisms driving CRC onset and progression, especially in relation to glucose metabolism reprogramming, are not fully understood and represent an emerging field of research. The review aims at providing new insights into the role that glucose metabolism reprogramming plays in the progression of CRC progression together with its resistance to treatment. Ultimately, these insights strive to diminish the risks of CRC metastasis and recurrence.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.